Characteristic | Training cohort(n = 119) | Validation cohort(n = 52) | P value |
---|---|---|---|
Age (mean ± SD, years) | 43.34 ± 12.5 | 44.81 ± 13.1 | 0.49 |
Gender | 0.44 | ||
 Male | 95 | 38 |  |
 Female | 24 | 14 |  |
Histology | 0.79 | ||
 Differentiated Non-keratinising | 62 | 26 |  |
 Undifferentiated  Non-keratinising | 57 | 26 |  |
T stage | 0.13 | ||
 T1 | 17 | 6 |  |
 T2 | 21 | 10 |  |
 T3 | 40 | 26 |  |
 T4 | 41 | 10 |  |
N stage | 0.11 | ||
 N0 | 10 | 2 |  |
 N1 | 41 | 14 |  |
 N2 | 53 | 22 |  |
 N3 | 15 | 14 |  |
Overall stage | 0.71 | ||
 I | 1 | 0 |  |
 II | 14 | 5 |  |
 III | 50 | 19 |  |
 IV | 54 | 28 |  |
Treatment | 0.24 | ||
 A | 14 | 8 |  |
 B | 56 | 28 |  |
 C | 5 | 5 |  |
 D | 44 | 11 |  |
EA-IgA | |||
 Positive | 38 | 15 | 0.82 |
 Negative | 81 | 37 |  |
VCA-IgA | |||
 Positive | 42 | 33 | 1.00 |
 Negative | 77 | 19 |  |
Smoking | 1.00 | ||
 Yes | 57 | 25 |  |
 No | 62 | 27 |  |
 Variance_T1 | 7.67 ± 0.71 | 7.64 ± 0.70 | 0.77 |
 IQR_T1 | 4.34 ± 0.76 | 4.37 ± 0.69 | 0.81 |
 Skewness_T2 | −1.79 ± 0.70 | −1.96 ± 0.72 | 0.16 |
 Kurtosis_T1H | 6.62 ± 2.29 | 6.71 ± 1.55 | 0.80 |
 HGLZE_T2H | 2.87 ± 0.43 | 2.92 ± 0.39 | 0.45 |
 HGLZE_T1 | 3.03 ± 0.41 | 3.16 ± 0.42 | 0.06 |
 DV_T1 | 22.17 ± 2.16 | 22.51 ± 2.10 | 0.34 |
 Kurtosis_T1L | 8.24 ± 3.82 | 7.69 ± 2.92 | 0.35 |
 LDLGLE_T1 | 145.67 ± 11.28 | 147.02 ± 11.15 | 0.47 |
 Kurtosis_T2 | 9.04 ± 9.04 | 8.18 ± 4.83 | 0.52 |
 HGLZE_T2L | 2.55 ± 0.51 | 2.44 ± 0.46 | 0.19 |
 Minimum_T1 | −1.84 ± 0.44 | − 1.75 ± 0.42 | 0.22 |
 GLNU_T1 | 5.24 ± 2.51 | 5.52 ± 2.40 | 0.49 |
Prognosis | 0.64 | ||
 Disease progression | 51 | 25 |  |
 Non-disease progression | 68 | 27 |  |